Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Group 1: Control	53
Overall Study	STARTED	Group 2: Raloxifene 60 mg	53
Overall Study	STARTED	Group 3: Raloxifene 30 mg	53
Overall Study	STARTED	Group 4: Lovaza 4 gm	54
Overall Study	STARTED	Group 5: Lovaza 4 gm and Raloxifene 30 mg	53
Overall Study	COMPLETED	Group 1: Control	47
Overall Study	COMPLETED	Group 2: Raloxifene 60 mg	38
Overall Study	COMPLETED	Group 3: Raloxifene 30 mg	36
Overall Study	COMPLETED	Group 4: Lovaza 4 gm	49
Overall Study	COMPLETED	Group 5: Lovaza 4 gm and Raloxifene 30 mg	44
Overall Study	NOT COMPLETED	Group 1: Control	6
Overall Study	NOT COMPLETED	Group 2: Raloxifene 60 mg	15
Overall Study	NOT COMPLETED	Group 3: Raloxifene 30 mg	17
Overall Study	NOT COMPLETED	Group 4: Lovaza 4 gm	5
Overall Study	NOT COMPLETED	Group 5: Lovaza 4 gm and Raloxifene 30 mg	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00723398/flow